|本期目录/Table of Contents|

[1]王玮 王琦 吴海斌 张永生 焦扬.COPD肺络微型癥瘕的分子病理学阐释[J].环球中医药,2016,9(08):946-949.[doi:10.3969/j.issn.1674-1749.2016.08.011]
　Wang Wei,Wang Qi,WU Hai-bin,et al.The explanation of molecular pathology of micro-zhengjia in feiluo with COPD[J].,2016,9(08):946-949.[doi:10.3969/j.issn.1674-1749.2016.08.011]
点击复制

COPD肺络微型癥瘕的分子病理学阐释()
     
分享到：

《环球中医药》[ISSN:1006-6977/CN:61-1281/TN]

卷:
第9卷
期数:
2016年08期
页码:
946-949
栏目:
理论探讨
出版日期:
2016-08-06

文章信息/Info

Title:
The explanation of molecular pathology of micro-zhengjia in feiluo with COPD
作者:
王玮 王琦 吴海斌 张永生 焦扬
100029 北京中医药大学[王玮(博士研究生)]; 北京中医药大学东方医院呼吸病科(王琦、吴海斌、张永生、焦扬)
Author(s):
Wang Wei; Wang Qi; WU Hai-bin; et al.
Beijing University of Chinese medicine,Beijing 100029,China
关键词:
慢性阻塞性肺疾病;  肺络;  微型癥瘕;  分子生物学;  气道重构
Keywords:
Chronic obstructive pulmonary disease;  Feiluo;  Micro-zhengjia;  Molecular biology;  Airway remodeling
分类号:
R256.14
DOI:
10.3969/j.issn.1674-1749.2016.08.011
文献标志码:
A
摘要:
结合中医络病、癥瘕、聚散理论,笔者认为慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)的基本病机是微型癥瘕痹阻肺络,该假说与西医的气道重构具有一致性。在传统中医四诊的基础上,本文将现代分子生物学理论与COPD辨证分型相结合,揭示了肺络微型癥瘕的内涵,为COPD的临床辨证和个体化治疗提供新的参考依据,同时也为药物作用机制研究奠定基础。
Abstract:
Combined with the theories of collateral disease, abdominal mass and the theory of accumulating and dissipating in Chinese medicine, we consider that micro-zhengjia in feiluo is the basic pathogenesis in COPD, and the hypothesis has coherence with airway remodeling in Western medicine. On the basis of four diagnostic methods of TCM, we combine the theory of modern molecular biology with COPD syndrome differentiation to reveal the connotation of micro-zhengjia in feiluo. It not only provides the reference basis of syndrome differentiation and individual treatment of COPD, but also lays a foundation of study of mechanism of medicine.

参考文献/References:

[1] GOLD Executive Committee.Global strategy for the diagnosis,management,and prevention of chronic obstructive pulmonary disea -se(Revised 2015)[EB/OL].
[2015-7-25].http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html
[2] World Health Organization. The world health report 2000 - Health systems: improving performance[EB/OL].
[2015-7-25]. http//www.who.int/whr/2000/en/statistics.htm.2000.
[3] 王琦,吴海斌,张永生,等. “肺络微型癥瘕”与COPD气道重构的相关性探讨[J]. 北京中医药大学学报,2012,35(2):130-133.
[4] Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease[J]. Lancet,2004,364(9435):709-721.
[5] 白晓旭,王琦,张永生,等.慢性阻塞性肺疾病的肺络癥、瘕、聚、散理论[J]. 中医杂志,2012,53(20):1717-1719.
[6] 王玮,王琦.AECOPD的气络、血络理论[J].光明中医,2015,30(1):4-6.
[7] 白晓旭,王琦,吴海斌,等.益气消癥方对慢性阻塞性肺疾病稳定期患者肺功能和血流变的影响[J]. 中华中医药杂志,2015,30(12):4257-4260.
[8] 白晓旭,焦扬,王琦,等.益气消癥方对慢性阻塞性肺疾病模型大鼠MMP-9和TIMP-1表达的影响[J]. 中华中医药杂志,2014,29(6):1974-1977.
[9] 李岩,赵雁,黄启福,等.中医络病的现代认识[J]. 北京中医药大学学报报,2002,25(3):1-5.
[10] 周玉民,王辰,姚婉贞,等.职业接触粉尘和烟雾对慢性阻塞性肺疾病及呼吸道症状的影响[J]. 中国呼吸与危重监护杂志,2009,8(1):6-10.
[11] Peter J. Barnes. Oxidative Stress in COPD.Studies on Respiratory Disorders[M].New Jersey:Humana Press,2014:115-129.
[12] Naiki Y,Michelsen KS,Zhang W,et al. Transforming growth factor beta differentially inhibits Mgo88-dependant,but not TRAM- and TRIF-dependant,Lipopolysaccharide-induced TLR4 signaling[J].J Biol Chem,2005,280(7):5491-5495.
[13] Lu W,Zheng JP Zheng. The function of mucins in the COPD airway[J]. Current Respiratory Care Reports,2013,2(3):155-166.
[14] Rogers DF.Physiology of airway mucus secretion and pathophysiology of hypersecretion[J]. Respir Care,2007,52(9):1134-1146.
[15] Wen FQ,Liu X,Manda W,et al. Th2 cytokine-enhanced and TGF-BETA enhanced vascular endothelial growth factor production by cultured human airway smooth musclecellsis attenuated by IFN-gamma and corticosteroids[J]. J Allergy Clin Immunol,2003,111(6):1307-1318.
[16] Demedts IK, Demoor T, Bracke KR,et al. Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema[J].Respir Res, 2006,7(1):53.
[17] Lapperre TS,Willems LN,Timens W,et al. Small airways dysfunction and neutrophilic inflammation in bronchial biopsies and BAL in COPD[J]. Chest,2007,131(1):53-59.

相似文献/References:

[1]杨云霜 张蓉 杨金亮 李延晖 邹梦颖.慢性阻塞性肺疾病季节性发病中医机理 探讨[J].环球中医药,2013,6(05):342.
[2]乐一萍,孙燕妮.中医防治慢性阻塞性肺疾病的机制研究进展[J].环球中医药,2013,6(03):226.
　LE Yi ping,SUN Yan ni..The progress of Chinese medicine for prevention and treatment of chronic obstructive pulmonary disease mechanisms[J].,2013,6(08):226.
[3]李京,伍燕兵,曹志新,等.健脾益肺汤治疗肺脾气虚型慢性阻塞性肺疾病无创机械通气患者临床研究[J].环球中医药,2013,6(10):725.
　LI Jing,WU Yan bing,CAO Zhi xin,et al.Clinical research of Jianpi Yifei Decoction on treating COPD patients of lungspleen qi deficiency who need noninvasive mechanical ventilation[J].,2013,6(08):725.
[4]曹芳,吴志松,王玮,等.周平安教授诊治慢性阻塞性肺疾病经验[J].环球中医药,2015,8(12):1496.[doi:10.3969/j.issn.1674.1749.2015.12.023]
[5]阮越勇,王蓓蕾,李想,等.慢性阻塞性肺疾病稳定期中医证候与理化检测指标的相关性研究[J].环球中医药,2017,10(04):401.[doi:10.3969/j.issn.1674-1749.2017.04.005]
　RUAN Yueyong,WANG Beilei,LI Xiang,et al.Relevant research of TCM syndrome and physical and chemical detection index of stable COPD[J].,2017,10(08):401.[doi:10.3969/j.issn.1674-1749.2017.04.005]
[6]滑宬 何明.从虚、痰、气、瘀论治慢性阻塞性肺病经验[J].环球中医药,2017,10(07):753.[doi:10.3969/j.issn.1674-1749.2017.07.023]
[7]薛柏华,张伟,董洪珍.慢性阻塞性肺疾病合并营养不良的中医证型及治疗的相关研究进展[J].环球中医药,2017,10(10):1178.[doi:10.3969/j.issn.1674-1749.2017.10.038]
　XUE Baihua,ZHANG Wei,DONG Hongzhen..Research progress of TCM syndromes and treatment of chronic obstructive pulmonary disease combined with malnutrition[J].,2017,10(08):1178.[doi:10.3969/j.issn.1674-1749.2017.10.038]

备注/Memo

备注/Memo:
基金项目: 国家自然科学基金(81473659); 北京中医药大学校级自主课题(2015-JYB-XS180)
作者简介: 王玮(1987- ),女,2014级在读博士研究生。研究方向:肺系疑难病诊疗研究。E-mail:357912695@qq.com
通讯作者: 焦扬(1963- ),女,博士,主任医师,教授,博士生导师。研究方向:肺系疑难病诊疗研究。E-mail:yangjiao2013@sina.com
更新日期/Last Update: 2016-08-06